Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

Veracyte has announced that it has secured Medicare coverage for its TrueMRD monitoring test, which is intended for patients with muscle-invasive bladder cancer. This test aims to assist in monitoring the disease and potentially improving patient outcomes.